LVGN7409 + LVGN3616 + LVGN6051

This is a **combination therapy** of three investigational monoclonal antibodies, each targeting distinct immune checkpoint or co-stimulatory molecules: - **LVGN7409** (dalnicastobart) is a recombinant monoclonal antibody agonist targeting CD40, designed to activate the CD40 receptor in a selective FcγRIIB-dependent manner, promoting T-cell activity and antitumor immune responses[1][4][7]. - **LVGN3616** (pradusinstobart) is a humanized monoclonal antibody targeting PD-1 (programmed cell death protein 1), serving as an immune checkpoint inhibitor to restore T-cell-mediated immune responses against tumors[1]. - **LVGN6051** (exlinkibart) is a monoclonal antibody agonist targeting 4-1BB (CD137), which enhances T-cell activation and survival in the presence of FcγRIIB, potentially resulting in decreased tumor growth[1][7]. Developed by Lyvgen Biopharma, this combination is being evaluated in advanced solid tumors and other malignancies. The drugs are supplied by Lyvgen Biopharma in ongoing clinical trials, primarily via intravenous administration, with primary indications in **metastatic solid tumors** including gastric cancer, sarcoma, and carcinoma[2][7].

Brand names

dalnicastobartpradusinstobart

Other names

LVGN 7409LVGN7409LVGN-7409LVGN 3616LVGN3616LVGN-3616LVGN 6051LVGN6051LVGN-6051